KKR to Acquire Integer Holdings in $5.7 Billion Medical Device Take-Private

KKR has signed a definitive merger agreement to acquire Integer Holdings Corporation, a publicly traded medical device development and contract manufacturing company, for approximately $5.7 billion in enterprise value. The offer price of $127 per share in cash represents a premium of approximately 51.8% over Integer's closing price prior to the announcement of its strategic review. The transaction is expected to close by the end of 2026 and is not subject to a financing condition.

KKR will acquire all outstanding shares of Integer through a subsidiary, taking the company private. The deal was signed following a strategic review initiated by Integer's board of directors. Financing will consist of a combination of equity and committed debt, with no financing condition attached to the agreement.

Integer Holdings is one of the largest contract manufacturers serving the medical device industry, with particular strength in cardiovascular devices, neuromodulation systems, and cardiac rhythm management products. The company provides design and manufacturing services to major medical technology companies, positioning it as a critical supplier rather than a branded end-product manufacturer. This distinction makes Integer's revenue streams relatively stable, as its customers depend on it for specialized production capabilities that are difficult to replicate.

For KKR, the acquisition represents a bet on the structural growth of the medical device outsourcing market. As large medtech companies increasingly focus on core competencies and outsource complex manufacturing, contract manufacturers like Integer stand to benefit from growing volumes across multiple product categories. The take-private structure gives KKR the flexibility to invest in capacity expansion, technology upgrades, and potential bolt-on acquisitions without the quarterly earnings pressures of public markets.

The transaction raises several areas requiring careful legal analysis. FDA quality systems, product recall history, customer audit rights, and manufacturing facility licenses must be reviewed on a facility-by-facility basis. Long-term production and supply agreements with Integer's customers will need to be examined for change-of-control provisions, exclusivity clauses, price adjustment mechanisms, and volume commitments — these contractual terms are central to the valuation.

The alignment of debt financing commitments with the transaction timeline and KKR's reverse termination fee obligations in the event of financing failure are additional points of focus. Given Integer's role as a sole-source or limited-source supplier for certain critical components, supply continuity representations and post-closing transition planning will also be important.

The transaction is one of two major healthcare take-privates announced in the same period, alongside the Curium–Lantheus radiopharmaceutical deal. Together, they reflect continued private equity appetite for healthcare infrastructure assets — companies that provide essential services to the broader healthcare system rather than bearing direct drug approval or reimbursement risk.

ULF New York Consulting Inc. advises Turkish companies on U.S. market entry, cross-border M&A, and regulatory compliance. This analysis is provided for informational purposes only and does not constitute legal advice.